drugset / Trial / NCT04555733

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

NCT04555733

Phase 1 Completed 26 enrolled Eisai Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

The primary objective of this study is to assess the pharmacokinetics (PK) of lemborexant and metabolites (M4, M9, and M10) in plasma in healthy Chinese participants following single and multiple oral doses of lemborexant.

Timeline

Start
2020-10-26
Primary completion
2021-01-13
Completion
2021-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 5 mg Oral
Subject Lemborexant Small molecule 10 mg Oral
Subject Lemborexant Small molecule 25 mg Oral

Indications

No indication recorded.